# China NMPA Drug Inspection - Jianmin Group Yekaitai Traditional Chinese Medicine (Suizhou) Co., Ltd. - Digestive tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/jianmin-group-yekaitai-traditional-chinese-medicine-suizhou-co-ltd/c2cce1dd-7dea-4480-81ba-4d26a0905579/
Source feed: China

> China NMPA drug inspection for Jianmin Group Yekaitai Traditional Chinese Medicine (Suizhou) Co., Ltd. published March 29, 2022. Drug: Digestive tablets. On March 29, 2022, the Hubei Provincial Drug Administration released its first Drug Quality Bulletin of the year, detail

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Hubei Province Drug Quality Bulletin (Issue 1, 2022)
- Company Name: Jianmin Group Yekaitai Traditional Chinese Medicine (Suizhou) Co., Ltd.
- Publication Date: 2022-03-29
- Drug Name: Digestive tablets
- Inspection Finding: Inspection: Weight difference
- Action Taken: Necessary control measures such as sealing, seizure, suspension of sales, and recall will be implemented, and the production enterprise and the sampled unit will be investigated and dealt with in accordance with relevant laws and regulations.
- Summary: On March 29, 2022, the Hubei Provincial Drug Administration released its first Drug Quality Bulletin of the year, detailing the results of random inspections across drug production, distribution, and medical use units. The report identifies 28 batches of drugs that failed to meet quality standards. Involved companies include Hubei Shenlongyuan Pharmaceutical Co., Ltd., Jianmin Group Yekaitai (Suizhou) Co., Ltd., and Hubei Fuguang Pharmaceutical Co., Ltd., among others. Main violations identified during testing included physical discrepancies such as weight variation and incorrect pH values, as well as more serious safety concerns like excessive sulfur dioxide residues and high mercury oxide limits. Several traditional Chinese medicine products failed identification tests and appearance standards, while pharmaceutical packaging materials were found to have excessive solvent residues. Regulatory enforcement is based on the Chinese Pharmacopoeia (2015 and 2020 editions) and National Pharmaceutical Packaging Material Standards. In response, the administration has ordered immediate control measures, including sealing, seizing, and recalling the non-compliant batches. Relevant departments are required to investigate the manufacturers and tracing drug sources, especially where counterfeiting is suspected. Cases involving potential criminal activity will be transferred to public security organs for prosecution.

Company: https://www.globalkeysolutions.net/companies/jianmin-group-yekaitai-traditional-chinese-medicine-suizhou-co-ltd/fcdc79e9-47f0-47ec-950b-906f04e83b3f/